CanBas Co., Ltd.
Stock Price Chart
2026/09/30 18:46 UpdatedPrice Trend
2026/09/30 18:46 UpdatedPrice & Trading Details
2026/09/30 18:46 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/09/01Financial Performance
2026/09/27 UpdatedNo financial data available
Latest IR Information
-
Notice Regarding Issuance of New Shares as Restricted Stock Compensation
As part of the stock-based compensation program, 57,000 shares will be issued under a restricted stock compensation plan. The issue price is 719 yen per share, total 40,983,000 yen. The recipients are six directors, and the transfer restriction period runs...
Read more -
Fiscal Year Ending June 2026 Earnings Briefing
As a drug discovery company, CanBas explains its cancer drug research and development status, clinical data, future trial plans, and progress in the development pipeline. The briefing centers on CBP501 clinical Phase 2 data, the potential of three-drug combination therapy,...
Read more -
Please ensure to extract the formal title listed in the PDF and use it as is. Do not generate or modify the title on your own
There are many unknowns, but it appears to be a materials introducing business plans and organizational structure, with no specific settlement-related figures verifiable from the excerpt. It is not definitively known whether earnings information exists.
Read more -
Financial Summary for the Year Ending June 2026 (Japanese GAAP) (Consolidated)
For the year ended June 2026, operating loss was 1,358 million yen, ordinary loss was 1,307 million yen, and net loss attributable to owners of the parent was 1,308 million yen. R&D expenses increased, with CBP501-related costs as the main...
Read more -
Notice regarding Schedule of Recording Non-operating Income
Recognized foreign exchange gain of 7,570 thousand yen as non-operating income. Cumulative for the fourth quarter amounts to a foreign exchange gain of 46,449 thousand yen recorded as non-operating income. This matter is reflected in the June 2026 period Financial...
Read more
Latest News (5 items)
Company Information
About
CanBas Co., Ltd., a clinical stage biopharmaceutical company, engages in the basic research and clinical development of anti-cancer drugs. It develops CBP501, a compound which regulates the regulatory function of the protein calmodulin in Phase 2 clinical trials targeting non-small cell lung cancer; and CBS9106 for patients with advanced solid tumors. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.
